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Cardiovascular disease is the leading cause of morbidity and mortality in patients with end-stage renal disease.
It accounts for nearly half of the mortality in end-stage renal disease patients on maintenance dialysis treatment.
The spectrum of cardiovascular disease is diverse, including vascular disease and myocardial disease, and the
two commonly coexist and are interrelated with each other. Apart from considering the traditional Framingham
risk factors, there is increasing recognition of the importance of non-traditional risk factors in predisposing
patients with end-stage renal disease to this high incidence of cardiovascular complications, including excessive
calcium phosphorus load, hyperparathyroidism, anemia, hemodynamic overload, inflammation, increased
asymmetric dimethylarginine and oxidative stress. Cardiovascular disease in end-stage renal disease patients
commonly manifests as ischemic heart disease or acute coronary syndrome, stroke, peripheral vascular disease
and congestive heart failure. According to the United States Renal Data System, the annual incidence of new-
onset ischemic heart disease, stroke, peripheral vascular disease and congestive heart failure was estimated to
be approximately 5%, 1%, 7% and 7%, respectively. In order to improve the cardiovascular outcomes of end-
stage renal disease patients receiving maintenance dialysis therapy, a better understanding of the nature and
severity of cardiovascular disease as well as risk factors associated with the different cardiovascular complications
is required. [Hong Kong J Nephrol 2006;8(1):10–6]
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INTRODUCTION
A special report from the National Kidney Foundation
Task Force on Cardiovascular Disease in Chronic
Kidney Disease has documented at least a 10- to 30-
fold higher risk of cardiovascular mortality in patients
with end-stage renal disease (ESRD) treated by dialysis
or transplant as compared to an age-, gender- and race-
matched control population [1]. According to the recent
10-year data from the Hong Kong Renal Registry, up
to 50% of the mortality in dialysis patients is accounted
for by cardiovascular causes. A recent prospective
longitudinal follow-up study performed in a Hong Kong
Chinese peritoneal dialysis population also revealed the
rate of cardiovascular mortality to be as high as 65%
[2]. Using multivariable Cox regression analysis, back-
ground atherosclerotic vascular disease was associated
with adjusted hazard ratios of 2.65 (95% confidence
intervals [CI], 1.46–4.80) and 3.20 (95% CI, 1.43–
7.13) for mortality and cardiovascular death, respec-
tively. Having a known history of heart failure also
increased the cardiovascular mortality risk indepen-
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dently by 3.31-fold (95% CI, 1.36–8.08) in patients on
maintenance peritoneal dialysis [3], indicating the
importance of cardiovascular disease in predicting the
outcome of these patients.
Indeed, the association between kidney failure and
increased cardiovascular risk has been extensively
reported in the literature [4–7]. A pooled analysis of
data from four community-based studies including
the Atherosclerosis Risk in Communities Study, Cardio-
vascular Health Study, Framingham Heart Study, and
Framingham Offspring Study has clearly demonstrat-
ed that chronic kidney disease is a risk factor for the
composite endpoint of all-cause mortality and
cardiovascular disease in the general population [7].
In another recent study by Go et al, an independent
graded association was observed between a reduced
estimated glomerular filtration rate and the risk of death,
cardiovascular events and hospitalization in a large
community-based population [8]. This indicates that
kidney dysfunction is an independent predictor of an
enhanced cardiovascular risk and that the more severe
the kidney dysfunction, the greater the cardiovascular
risk.
This review aims to provide an overview of the
spectrum, prevalence and severity of cardiovascular
disease and briefly discuss the potential risk factors
associated with the different cardiovascular complica-
tions in ESRD patients. Furthermore, the prognostic
importance of the different cardiovascular complica-
tions in ESRD patients will be discussed.
VASCULAR DISEASE IN UREMIA
In ESRD patients, it is important to consider two primary
categories of cardiovascular complications, namely
vascular disease and cardiomyopathy. Vascular disease
in uremia encompasses two main subtypes, including
atherosclerosis and vascular calcification, which lead
to large-vessel remodeling or arteriosclerosis.
Vascular/valvular calcification
The presence of vascular and valvular calcification is
associated with both atherosclerosis and arteriosclerosis
in ESRD patients. Calcification occurring within the
intimal layer and plaque area is characteristic of
atherosclerotic disease and is associated with luminal
stenosis and distal ischemia. On the other hand, calci-
fication present within the medial layer, also known as
Monckeberg’s calcinosis, has been largely attributed
to uncontrolled hyperphosphatemia and increased
calcium-phosphorus product. It has a classic tram-line
appearance on plain radiographs and is associated with
stiffening of the arteries and loss of vascular compli-
ance. Compared to non-uremic patients with only the
intimal type of calcification, uremic patients frequently
exhibit both intimal and medial types of calcification,
but the intimal calcification is usually more extensive
and of greater severity [9].
The presence and severity of arterial calcification
has been clearly shown to predict an increased mortality
and cardiovascular death in ESRD patients [10]. By
classifying arterial calcification as intimal or medial
using plain radiographs of the pelvis and the thigh,
London et al showed that intimal calcification is
associated with the highest mortality while medial
calcification is also a strong prognostic marker of all-
cause and cardiovascular mortality [11]. Study in the
general population showed that total coronary artery
calcium score is useful in identifying a high-risk group
of asymptomatic subjects with clinically important
silent myocardial ischemia [12]. In chronic kidney
disease patients, coronary artery calcium score is also an
independent predictor of atherosclerotic burden [13].
On the other hand, the degree of coronary calcification
is an important determinant of arterial stiffening [14].
The degree of arterial stiffening as denoted by aortic
pulse wave velocity is also an important predictor of
mortality and cardiovascular death in dialysis patients
[15]. Increased arterial stiffening or arteriosclerosis is
associated with thickened, dilated and non-compliant
arteries [16], predisposing the patient to greater left
ventricular hypertrophy [17] by decreasing arterial
distensibility and enhancing arterial wave reflection,
thus increasing the pulsatile work of the heart. Arterio-
sclerosis also increases the risk of ischemic heart disease
by decreasing subendocardial coronary perfusion [17].
Our recent study showed that cardiac valvular
calcification is a marker of generalized atherosclerosis
in dialysis patients [18]. Greater carotid intima-media
thickness and more calcified plaque were observed in
peritoneal dialysis patients with cardiac valvular
calcification. Another study by Varma et al showed a
greater prevalence of atherosclerotic vascular disease
among hemodialysis patients with calcification of
the mitral or aortic valve compared to those with no
calcification [19], suggesting that calcification and ath-
erosclerosis are indeed closely associated phenomena
in patients with ESRD. Our study also demonstrated
the importance of cardiac valvular calcification in pre-
dicting mortality and cardiovascular death in chronic
peritoneal dialysis patients [20].
There is an increasing recognition of a high fre-
quency of coronary artery calcification in patients on
dialysis, with a reported prevalence ranging from 40%
to 100% [21–24]. According to one of the earlier series
by Braun et al, the coronary artery calcium score
assessed using electron beam computed tomography
was at least 2.5- to 5-fold higher in dialysis patients
than in non-dialysis patients. Of importance is that
over half of these patients also had calcification of both
the mitral and aortic valves. In addition, a repeat
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examination after 1 year showed a marked tendency
for progression of the coronary artery calcification [21].
This is very much in keeping with another landmark
study by Goodman et al, clearly demonstrating the
severity of coronary artery calcification in young
adults undergoing dialysis and the progressive nature
of coronary artery calcification in dialysis patients.
In Goodman et al’s study, patients with coronary art-
ery calcification were noted to be older, dialyzed
for a longer duration, and had higher mean serum
phosphorus level with resulting higher calcium-
phosphorus product. Of greater significance is that
the daily calcium intake was higher among those with
coronary artery calcification [22]. This finding under-
scores the importance of not only uncontrolled hyper-
phosphatemia but also excess calcium load in pre-
disposing dialysis patients to an increased risk of
vascular calcification. Indeed, a recent study by
Chertow and coworkers showed that calcium-based
phosphate binders are associated with progressive
coronary artery and aortic calcification, especially
when mineral metabolism is not well controlled [25].
Although the exact mechanism has yet to be identified,
it was suggested that calcium may directly or indirectly
adversely influence vascular calcification in hemodia-
lysis patients via parathyroid hormone.
Our recent survey in local Chinese peritoneal
dialysis patients indicated a prevalence of 32% for
cardiac valvular calcification detected using echo-
cardiography [26]. Apart from increasing age, diabetes
and high calcium-phosphorus product, we demon-
strated an important association between inflammation
as denoted by C-reactive protein and malnutrition as
denoted by serum albumin with valvular calcification
in chronic peritoneal dialysis patients [26]. A similar
association between C-reactive protein and coronary
artery calcium accumulation was also observed in a
subsequent study by Oh et al [27], indicating an
important link between inflammation and calcification.
There is also emerging data to suggest that serum fetuin-
A (alpha2-Heremans Schmid glycoprotein; AHSG), a
circulating calcification inhibitor in vivo and a negative
acute phase protein, may be an important mediator
of vascular calcification in patients with ESRD [28].
Sera from dialysis patients with deficient fetuin-A
concentration showed an impaired ex vivo capacity
to inhibit calcium-phosphorus precipitation that could
be reversed by adding purified fetuin-A into the sera
[28]. In the study by Ketteler and coworkers, fetuin-A
is identified as an inflammation-related predictor of all-
cause mortality and cardiovascular death in hemodia-
lysis patients [28]. Stenvinkel’s group also reported a
strong correlation between fetuin-A and hypoalbumi-
nemia, and that fetuin-A appeared to be a stronger
predictor of mortality than C-reactive protein [29]. In
addition, we showed that low serum fetuin-A was
associated with more cardiac valvular calcification
and the malnutrition, inflammation and atherosclerosis
(MIA) syndrome, as well as a worse outcome in ESRD
patients receiving maintenance peritoneal dialysis,
suggesting that fetuin-A may be an important element
in calcification and MIA syndrome in dialysis patients
[30] and requires further evaluation.
Accelerated atherosclerosis
Atherosclerosis usually manifests as ischemic heart
disease (in the form of angina, myocardial infarction
or sudden cardiac death), cerebrovascular disease,
peripheral vascular disease and heart failure. An earlier
study by Parfrey and coworkers indicated that 22% of
the patients starting dialysis therapy had ischemic heart
disease manifesting as myocardial infarction (56%),
angina (82%), coronary bypass grafting (14%) or
coronary angioplasty (1%) [31]. The presence of ische-
mic heart disease is an adverse prognostic indicator in
dialysis patients. The mortality rate at 1 year and 2 years
after myocardial infarction was reported to be 59% and
73%, respectively, in dialysis patients [32]. However,
it is important to note that dialysis patients with ischemic
heart disease may not necessarily have large-vessel
disease. A previous study showed that nearly half of
non-diabetic dialysis patients with symptoms of myo-
cardial ischemia did not have large-vessel coronary
artery disease, which was defined as > 50% luminal
narrowing of major coronary vessels [33]. The myocar-
dial ischemia was hypothesized to be the combined
effects of volume overload and left ventricular hyper-
trophy, which leads to increased myocardial oxygen
demand. This suggests that ischemic heart disease in
dialysis patients may also occur as a result of severe
left ventricular hypertrophy in the absence of arterial
vascular disease.
Apart from traditional cardiovascular risk factors
such as age, gender, smoking, diabetes and hyperten-
sion, there is increasing evidence that non-traditional
risk factors are also important mediators of accelerated
atherosclerosis in ESRD patients. These include inflam-
mation, abnormal calcium-phosphorus metabolism,
increased oxidative stress, anemia, hyperhomocystein-
emia, hyperparathyroidism and altered nitric oxide
synthesis, of which inflammation is considered a major
pathogenic mechanism of atherosclerosis [34,35].
Using C-reactive protein as the prototype marker of in-
flammation, the prevalence of inflammation has been
reported to range from 20% to 50% in dialysis pa-
tients [36], although the cut-off levels used to define
inflammation varied in these different studies. Our
recent study showed that around 35% of Chinese
peritoneal dialysis patients showed evidence of
inflammation as defined by a C-reactive protein level
above 5 mg/L [3]. In addition, an elevated C-reactive
protein level was associated with a higher prevalence
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of atherosclerotic vascular disease and more severe
cardiac hypertrophy [3]. There is accumulating
evidence that C-reactive protein is a powerful marker
of all-cause mortality and cardiovascular death in
dialysis patients [37–39]. Of greater importance is the
finding that the risk associated with an elevated
C-reactive protein level appears to be independent of
other important risk factors such as background
cardiovascular disease, cardiac hypertrophy and
residual glomerular filtration rate [3]. In addition, C-
reactive protein contributes to the progression of carotid
atherosclerosis in dialysis patients [40], giving fur-
ther evidence of a causal role of inflammation for
atherosclerosis. Cellular adhesion molecule, which is
involved in leukocyte-endothelial activation and plays
a pivotal role in inflammation, has also been associated
with mortality and cardiovascular events in both pre-
dialysis [41] and peritoneal dialysis patients [42]. In
both hemodialysis and peritoneal dialysis patients,
increased levels of inflammation marker and cellular
adhesion molecule are associated with carotid
atherosclerosis [43,44]. The prognostic importance of
other inflammatory markers including interleukin-6 [45,
46] and fibrinogen [47] has also been demonstrated in
dialysis patients. There are recent data to suggest that
interleukin-6 may be a stronger predictor of mortality
and cardiovascular death in dialysis patients [48]. All
these findings are building up evidence to suggest that,
irrespective of the inflammatory markers used, the
presence of inflammation represents an important risk
predictor of cardiovascular complications and mortal-
ity and may play a key role in mediating accelerated
atherosclerosis in dialysis patients.
On the other hand, it is of interest to note that a
recent study showed stronger associations between
traditional cardiovascular risk factors and cardiovas-
cular mortality than novel risk factors such as inflam-
mation in elderly persons with chronic kidney disease
[48], giving evidence that traditional risk factors re-
main important mediators of cardiovascular disease in
the ESRD population and should not be overlooked.
MYOCARDIAL DISEASE IN UREMIA
Left ventricular hypertrophy
Cardiac hypertrophy is another major complication in
ESRD patients. Foley et al reported the presence of left
ventricular hypertrophy in 74% of patients starting
dialysis therapy [49]. Another recent cross-sectional
study observed an increase in left ventricular mass even
at the earliest stages of renal disease, with eccentric
left ventricular hypertrophy being the predominant
pattern [50]. With progressive decline in renal function,
a progressive increase in left ventricular mass was
observed, with more than 80% of patients on renal
replacement therapy having left ventricular hypertro-
phy, and with concentric left ventricular hypertrophy
being the predominant pattern. In addition, the pre-
valence of diastolic dysfunction increased in parallel
with changes in left ventricular mass [50].
There are numerous well-known risk factors
responsible for left ventricular hypertrophy in ESRD
patients. Hypertension and arteriosclerosis result in
pressure overload and give rise to a concentric pattern
of left ventricular hypertrophy (increased wall-to-lumen
ratio). Anemia, chronic volume expansion, hyperpara-
thyroidism and arteriovenous fistula, which result in a
volume overload state, are associated with ventricular
dilatation with left ventricular hypertrophy or so-called
eccentric left ventricular hypertrophy (a proportional
increase in left ventricular mass and diameter). Accord-
ing to a Canadian echocardiographic study, the pres-
ence of diabetes is associated with more concentric left
ventricular hypertrophy at the initiation of dialysis than
non-diabetics [49]. At autopsy, the left ventricular
hypertrophy in hypertensive diabetic patients was also
associated with more extensive fibrosis [51].
In a recent study, we demonstrated greater left
ventricular hypertrophy and dilatation as well as more
diastolic dysfunction among peritoneal dialysis pa-
tients with a previous history of volume overload [52],
giving evidence of the importance of volume control
in predisposing peritoneal dialysis patients to develop
left ventricular hypertrophy. Indeed, the degree of
sodium and fluid removal have been demonstrated to
be powerful predictors of mortality in patients on perito-
neal dialysis [53]. Recent re-analysis of the CANUSA
study also provided clear evidence that residual renal
function had a more important contribution than
peritoneal dialysis clearance to the overall survival of
peritoneal dialysis patients [54]. In addition, entering
urine volume reduced the association of residual renal
function with mortality in peritoneal dialysis patients,
suggesting that residual renal function may play a
significant role in maintaining volume control in
peritoneal dialysis [54]. More recently, we described
an important novel association between residual renal
function and left ventricular hypertrophy in peritoneal
dialysis patients [55]. Although the exact mechanism
has yet to be determined, our data suggest that worsen-
ing anemia, uremia, volume control and blood pressure
may all contribute to the more severe left ventricular
hypertrophy that is observed in anuric peritoneal
dialysis patients, requiring further investigation. A
recent study from our group also indicated that loss of
residual renal function was closely interrelated with
inflammation and cardiac hypertrophy in peritoneal
dialysis patients [2]. Patients with no residual renal
function and a greater degree of inflammation have the
most severe left ventricular hypertrophy compared to
patients with either factor alone. It is of importance to
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note that loss of residual renal function, inflammation
and cardiac hypertrophy also combined adversely
to enhance mortality and cardiovascular death in
peritoneal dialysis patients. Patients with all three risk
factors, namely loss of residual renal function, greater
inflammation and more severe cardiac hypertrophy,
have a 6.94-fold and 5.43-fold increased risk of all-cause
mortality and cardiovascular death, respectively [2].
On the other hand, elevated asymmetric dimethyl-
arginine, an endogenous inhibitor of nitric oxide and a
recently identified novel cardiovascular risk, is also
associated with concentric left ventricular hypertrophy
and left ventricular remodeling in dialysis patients [56].
Apart from clinical and biochemical factors, genetic
factors may also increase the predisposition to left
ventricular hypertrophy. As shown in our recent study,
the angiotensinogen M235T gene TT genotype is
associated with greater left ventricular hypertrophy and
left ventricular remodeling in Chinese peritoneal
dialysis patients [57]. This is in contrast to a study of a
Caucasian non-renal failure population [58] and a
Japanese dialysis population [59] showing that the DD
genotype of the angiotensin converting enzyme
insertion/deletion (I/D) gene is associated with more
severe left ventricular hypertrophy. This suggests that
the genetic predisposition for left ventricular hyper-
trophy may vary according to the racial population.
The degree of left ventricular hypertrophy and cavity
volume are both established to be important predictors
of mortality and cardiovascular death in ESRD [49]. A
recent study by Zoccali et al indicated the independent
prognostic value of echocardiographically determined
left ventricular systolic function for mortality and
cardiovascular risk prediction in dialysis patients [60].
In addition, the cardiovascular event risk was found to
be the highest among dialysis patients with both left
ventricular hypertrophy and systolic dysfunction [60].
Cardiac failure
Heart failure is the commonest manifestation of car-
diac dysfunction in patients on maintenance dialysis.
According to the cross-sectional survey by Harnett and
coworkers, which included both hemodialysis and
peritoneal dialysis patients, nearly one-third of the pa-
tients developed heart failure on initiation of dialysis, of
which 56% had further recurrences [61]. Even among
patients with no heart failure at baseline, around 25%
of patients developed heart failure at a rate of 7% per
year. In addition, the presence of heart failure was
associated with a worse prognosis in that median
survival was 36 months for patients with heart failure
at baseline compared to 62 months for patients with-
out heart failure. They also found that increasing age,
diabetes mellitus and ischemic heart disease were asso-
ciated with heart failure at initiation of dialysis, while
ischemic heart disease, anemia, hypoalbuminemia and
systolic dysfunction were important predictors of heart
failure recurrence [61]. The presence of ischemic heart
disease is associated with greater left atrial diameter,
greater left ventricular end-systolic diameter, lower
fractional shortening and, thus, more systolic
dysfunction [31]. Ischemic heart disease is also an
important risk factor associated with left ventricular
hypertrophy in dialysis patients [2]. In the Canadian
Prospective Cohort Study, which included 433 incident
dialysis patients, 74% had left ventricular hypertrophy
at baseline, 30% had left ventricular hypertrophy with
dilatation, and 15% had systolic dysfunction [49],
indicating that much of the cardiac hypertrophy and
dysfunction was already established by the time patients
started their dialysis therapy. This may also explain why
dialysis patients are prone to develop heart failure.
CONCLUSION
A high prevalence of cardiovascular disease is observed
in ESRD patients receiving dialysis therapy. This
usually constitutes a combination of vascular and myo-
cardial disease related to both traditional and non-
traditional risk factors. Most of these cardiovascular
complications are already established and advanced by
the time patients are started on dialysis treatment, thus
indicating the need for earlier and more active screening
for cardiovascular disease even before patients pro-
gress to end-stage kidney disease. Given the rising inci-
dence of cardiovascular complications and mortality
in dialysis patients, our data also raise the importance
of adopting a more proactive approach in managing
the different cardiovascular complications in ESRD pa-
tients starting dialysis therapy. More attention should
be focused on improving cardiovascular outcomes in
ESRD patients receiving maintenance dialysis therapy.
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